Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)

CNS Drug Reviews

Volumn 12, Issue 1, 2006, Pages 21-38

  Piomelli, Daniele ^a,b   Tarzia, Giorgio ^c   Duranti, Andrea ^c   Tontini, Andrea ^c   Mor, Marco ^d   Compton, Timothy R ^a   Dasse, Olivier ^a   Monaghan, Edward P ^a   Parrott, Jeff A ^a   Putman, David ^a  

^a Kadmus Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF URBINO   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Anandamide; Anxiety; Cannabinoids; Depression; Fatty acid amide hydrolase; Pain

Indexed keywords

ANALGESIC AGENT; ANANDAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; ION CHANNEL; UNCLASSIFIED DRUG;

AMES TEST; ANXIETY; DEPRESSION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HUMAN; LIVER MICROSOME; NONHUMAN; PAIN; REVIEW; ROTAROD TEST;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ANXIETY; BENZAMIDES; BRAIN; CANNABINOIDS; CARBAMATES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; NEURONS; PHARMACOKINETICS;

EID: 33746474287     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00021.x     Document Type: Review

References (51)

1. Basso E, Duranti, A., Mor, M., et al. Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom 2004;39:1450-1455.
2. Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110:1996-2002.
3. Beltramo M, di Tomaso E, and Piomelli D. Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1- naphthalenyl)-2H-pyran-2-one. FEBS Lett 1997;403:263-267.
4. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997;277:1094-1097.
5. Boger DL, Sato H, Lerner AE, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000;97:5044-5049.
6. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-281.
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87.
8. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98:9371-9376.
9. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 2004;101:10821-10826.
10. Désarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 1995;270:6030-6035.
11. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
12. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-691.
13. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002;121:149-158.
14. Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl- 3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005;313:352-358.
15. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synoptic signaling. Physiol Rev 2003;83:1017-1066.
16. Fu J, Gaetani S, Oveisi F, Lo Verme J, et al. Oleylethanalamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-93.
17. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999;2:358-363.
18. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102:18620-18625.
19. Guzman M, Lo Verme J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor PPAR-alpha. J Biol Chem 2004;E-publication April 26.
20. 1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004;19:1906-1912.
21. Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB. Characterisation of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1995;1257:249-256.
22. Hillard CJ, Campbell WB. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res 1997;38:2383-2398.
23. Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005;435:1108-1112.
24. Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: Comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 2005;146:467-476.
25. Iversen LL. The science of marijuana. Oxford: University Press, 2000.
26. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2005;147:281-288.
27. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76-81.
28. Lichtman AH, Leung D, Shelton C, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 2004;311:441-448.
29. Lodola A, Mor M, Hermann JC, Tarzia G, Piomelli D, Mulholland AJ. QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun (Comb) 2005:4399-4401.
30. LoVerme J, Fu J, Astarita G et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-19.
31. Makara JK, Mor M, Fegley D, et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 2005;8:1139-1141.
32. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418:530-534.
33. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996;300:227-236.
34. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2004;74:411-432.
35. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
36. Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA 2005;102:17852-17857.
37. Mor M, Rivara S, Lodola A, et al. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004;47:4998-5008.
38. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
39. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997;8:491-496.
40. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 1999;147:162-167.
41. Patel S, Roelke CT, Rademacher DJ, Hillard CJ. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005;21:1057-1069.
42. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-884.
43. Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001;414:209-212.
44. Schmid PC, Zuzarte-Augustin ML, Schmid HH. Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 1985;260:14145-14149.
45. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-778.
46. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
47. Tarzia G, Duranti A, Tontini A, et al. Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorg Med Chem 2003;11:3965-3973.
48. Tarzia G, Duranti A, Tontini A, et al. Synthesis and structure-activity relationships of FAAH inhibitors: Cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. Chem Med Chem 2005;6:1-11.
49. Ueda N, Yamamoto K, Yamamoto S, et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1995;1254:127-134.
50. 1 receptors. Neuropharmacology 2004;46:966-973.
51. 2 receptors. Science 2005;310:329-332.